HLB Group holds integrated IR Day on the 15th... Repick2 reveals growth strategy after FDA approval

Participation of 10 listed affiliates... Announcement of business status of five companies including HLB and HLB Therapeutics

Share major development schedules, including re-application for liver cancer new drug approval and RGN-259 phase 3 clinical trial

After securing its first new drug approved by the U.S. Food and Drug Administration (FDA), HLB Group is unveiling its group-wide follow-up growth strategy. The current status of the U.S. approval process for new liver cancer drugs and the clinical development performance of major affiliates are the main areas of interest at this corporate briefing session.

HLB Group announced on the 12th that it will hold the ‘2026 HLB Group IR Day’ for institutional investors and analysts in Yeouido, Seoul at 3 p.m. on the 15th.

The group's 10 listed affiliates will participate in this event, which is being held for the second time this year following last April. Among these, five companies, including HLB, HLB Innovation, HLB Therapeutics, HLB Panagine, and HLB Genex, will announce their major business achievements and mid- to long-term strategies. After the announcement, an integrated Q&A will be held in which all 10 listed companies participate.

HLB plans to explain the performance of ‘LYRFIGTU (ingredient name: lirafugratinib)’, a treatment for bile duct cancer that was recently approved by the FDA, and the current status of the approval process for rivoceranib and camrelizumab combination therapy, a first-line treatment for liver cancer.

In particular, the liver cancer treatment has completed re-application for approval with the FDA, and investors' attention is expected to focus on the future review schedule and commercialization preparation status.

HLB Therapeutics discloses the progress of phase 3 clinical trials and commercialization strategy for neurotrophic keratitis (NK) treatment ‘RGN-259’. RGN-259 is a pipeline that is about to announce the main results of phase 3 clinical trials, and attention is being paid to the extent to which the development schedule and follow-up plan will be concreted at this briefing session.

HLB Innovation introduces the current status of development of Verismo Therapeutics' next-generation CAR-T treatment, along with the growth strategy of the existing semiconductor business. We also plan to explain the bio business synergy with the recently acquired HLB Cell and the mid- to long-term business direction.

HLB Panazine announces its business expansion direction using the PNA-AOC new drug platform and spatial proteome-based AI diagnostic technology. HLB Genex shares the growth of its special enzyme business for semiconductors and food and its strategy for entering the new biomaterial field.

HLB Group plans to use this event as an opportunity to directly explain the business progress of its major affiliates to investors and expand communication with the capital market through regular integrated IR.

Lim Chang-yoon, vice president of HLB Group's investment division, said, “This IR Day is an opportunity to explain the business performance and future growth strategies of major affiliates to investors.” He added, “We will continue to strengthen communication with the market and increase the overall corporate value of the group based on the performance of core businesses.”